Welcome to our dedicated page for LifeStance Health Group SEC filings (Ticker: LFST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LifeStance Health Group filings document the company's outpatient mental healthcare business, Nasdaq-listed common stock and public-company governance. Its 8-K reports furnish quarterly and annual results, Regulation FD presentations, operating metrics, cash flow commentary and capital allocation disclosures.
The filing record also covers proxy matters, director elections, executive compensation, officer and board changes, equity incentive awards, share repurchase authorization, and common stock offering documents under shelf registration statements. These disclosures describe governance structure, securities registration, material agreements, stockholder selling activity, repurchases, and the risks and reporting obligations associated with LifeStance's virtual and in-person outpatient care model.
LifeStance Health Group director Kenneth A. Burdick reported compensation-related stock movements on March 9, 2026. He acquired common stock through vested restricted stock units and performance-based restricted stock units, with two grant or award acquisitions totaling 740,504 shares at a stated price of $0.00 per share.
To cover tax withholding obligations on these RSUs and PSUs, the issuer withheld 327,209 shares at $6.91 per share in three separate dispositions, which the footnotes clarify were not open-market sales. Following these transactions, Burdick directly held 3,425,315 shares, with an additional 46,511 shares held indirectly through Burdick Family LLC.
LifeStance Health Group, Inc. Chief Executive Officer David Bourdon reported stock-based compensation activity rather than open-market trading. On March 9, 2026, previously granted restricted stock units (RSUs) and performance-based restricted stock units (PSUs) vested, resulting in share awards recorded as acquisitions.
To cover tax withholding obligations tied to the vesting and net settlement of these RSUs and PSUs, the company withheld a total of 148,382 shares at a reported price of $6.91 per share across several transactions. The footnotes state these withholdings simply reduced the shares delivered to him and did not involve any open-market sales.
LifeStance Health Group, Inc. Chief Operating Officer Lisa K. Miller reported equity compensation activity involving restricted stock units and related tax withholding. On March 9, 2026, she acquired 26,836 shares of common stock at a stated price of $0.00 per share in a grant/award tied to vested performance-based restricted stock units previously granted on March 6, 2025.
On the same date, the issuer withheld 14,766 shares of common stock at $6.91 per share to satisfy tax obligations for vested RSUs and separately withheld 13,446 shares at $6.91 per share for tax obligations related to vested PSUs. Footnotes specify these withheld shares reduce the shares issued to Miller and do not constitute any open-market sale. After these transactions, she directly owned 329,201 shares of common stock.
LifeStance Health Group Chief People Officer Ann Varanakis reported compensation-related share activity in connection with vested restricted stock units (RSUs) and performance-based RSUs (PSUs) on March 9, 2026.
She acquired 26,836 and 59,789 shares of common stock at $0.00 per share through RSU and PSU settlements. To cover tax withholding obligations on these vestings, the issuer withheld a total of 44,963 shares at a reference price of $6.91 per share. The footnotes state these withholdings reduce shares delivered and do not involve any open-market sales. Following these transactions, Varanakis directly holds 422,037 shares of LifeStance common stock.
LifeStance Health Group director and officer Ryan Pardo reported equity compensation vesting and related tax withholding transactions in Common Stock. On March 9, 2026, he received stock awards of 40,254 and 105,711 shares at no cost as restricted and performance-based units vested.
To cover tax obligations on these vestings, the issuer withheld 12,280, 15,841, and 38,479 shares at $6.91 per share, which the footnotes state are not open-market sales. Following these transactions, Pardo directly owned 1,102,742 shares and had indirect exposure to 2,551,520 shares held by the Kimberly Pardo Irrevocable Trust, where he disclaims beneficial ownership beyond any pecuniary interest.
LifeStance Health Group, Inc. executive Ryan McGroarty reported equity compensation activity involving performance-based restricted stock units (PSUs) that vested on March 9, 2026. He acquired 127,878 shares of common stock from PSUs granted on March 17, 2025, and 65,168 shares from PSUs granted on March 24, 2025.
To cover tax withholding obligations on these PSU settlements, the issuer withheld 50,929 shares and 25,644 shares at a price of $6.91 per share. The footnotes state these withholdings reduced the shares delivered on vesting and did not involve any open-market sales.
After these transactions, McGroarty directly held 844,084 shares of LifeStance common stock.
LifeStance Health Group, Inc. Chief Technology Officer Vukasin Paunovich reported equity compensation activity tied to performance-based restricted stock units. On March 9, 2026, he acquired 62,935 shares of common stock at $0.00 per share upon vesting of previously granted PSUs. On the same date, 18,541 shares were withheld at $6.91 per share to satisfy tax withholding obligations, which the company notes did not involve any open-market sale. Following these transactions, Paunovich directly holds 309,296 shares of common stock.
LifeStance Health Group, Inc. appointed Lisa Miller as its Chief Operating Officer and Principal Operating Officer effective March 10, 2026. She has led practice operations at LifeStance since 2022 and previously served in senior operating roles at Invo Healthcare.
In her new role, Ms. Miller will receive an annual base salary of $485,000 and, beginning in calendar year 2026, will be eligible for an annual target bonus equal to 85% of base salary, based on performance. She will also receive annual equity awards under the 2021 Equity Incentive Plan with a current aggregate target grant date value of about $1,500,000 in time-based and performance-based restricted stock units vesting over three years, generally subject to continued employment and achievement of performance targets.
LifeStance Health Group, Inc. reported that Chief Medical Officer Stephanie Carin Eken acquired equity-based compensation in the form of restricted stock units. On March 5, 2026, she was granted 115,107 RSUs, each representing a contingent right to receive one share of LifeStance common stock.
The Form 4 classifies this as a grant or award acquisition at a price of $0.00 per share, typical for stock-based compensation. Following this grant, her directly held common stock and RSU-related interest totals 115,107 shares of LifeStance common stock on a contingent basis.
LifeStance Health Group, Inc. officer Ryan Pardo reported equity award activity in the company’s common stock. On March 5, 2026, he acquired 129,496 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock.
On March 6, 2026, 21,854 shares were withheld at $6.93 per share to cover tax obligations related to vested RSUs. The filing specifies that these withheld shares reduce the shares issued to him and do not constitute any open‑market sale.
After these transactions, he held 1,023,377 shares directly and 2,551,520 shares indirectly through the Kimberly Pardo Irrevocable Trust, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.